187 related articles for article (PubMed ID: 23872196)
1. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
Orie NN; Ledwozyw A; Williams DJ; Whittle BJ; Clapp LH
Prostaglandins Other Lipid Mediat; 2013 Oct; 106():1-7. PubMed ID: 23872196
[TBL] [Abstract][Full Text] [Related]
2. A comparison of vasodilation mode among selexipag (NS-304; [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide]), its active metabolite MRE-269 and various prostacyclin receptor agonists in rat, porcine and human pulmonary arteries.
Fuchikami C; Murakami K; Tajima K; Homan J; Kosugi K; Kuramoto K; Oka M; Kuwano K
Eur J Pharmacol; 2017 Jan; 795():75-83. PubMed ID: 27919660
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.
Benyahia C; Boukais K; Gomez I; Silverstein A; Clapp L; Fabre A; Danel C; Leséche G; Longrois D; Norel X
Prostaglandins Other Lipid Mediat; 2013 Dec; 107():48-55. PubMed ID: 23850788
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
Morrison K; Studer R; Ernst R; Haag F; Kauser K; Clozel M
J Pharmacol Exp Ther; 2012 Dec; 343(3):547-55. PubMed ID: 22918043
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents.
Benyahia C; Ozen G; Orie N; Ledwozyw A; Louedec L; Li F; Senbel AM; Silverstein A; Danel C; Longrois D; Clapp LH; Norel X; Topal G
Prostaglandins Other Lipid Mediat; 2015 Sep; 121(Pt A):46-52. PubMed ID: 26362969
[TBL] [Abstract][Full Text] [Related]
6. Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Gatfield J; Menyhart K; Wanner D; Gnerre C; Monnier L; Morrison K; Hess P; Iglarz M; Clozel M; Nayler O
J Pharmacol Exp Ther; 2017 Jul; 362(1):186-199. PubMed ID: 28476928
[TBL] [Abstract][Full Text] [Related]
7. A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery.
Kuwano K; Hashino A; Noda K; Kosugi K; Kuwabara K
J Pharmacol Exp Ther; 2008 Sep; 326(3):691-9. PubMed ID: 18552131
[TBL] [Abstract][Full Text] [Related]
8. Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
Morrison K; Ernst R; Hess P; Studer R; Clozel M
J Pharmacol Exp Ther; 2010 Oct; 335(1):249-55. PubMed ID: 20660124
[TBL] [Abstract][Full Text] [Related]
9. Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors.
Orie NN; Clapp LH
Eur J Pharmacol; 2011 Mar; 654(3):258-65. PubMed ID: 21185823
[TBL] [Abstract][Full Text] [Related]
10. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.
Whittle BJ; Silverstein AM; Mottola DM; Clapp LH
Biochem Pharmacol; 2012 Jul; 84(1):68-75. PubMed ID: 22480736
[TBL] [Abstract][Full Text] [Related]
11. Prostanoid EP₂ Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells.
Patel JA; Shen L; Hall SM; Benyahia C; Norel X; McAnulty RJ; Moledina S; Silverstein AM; Whittle BJ; Clapp LH
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103548
[TBL] [Abstract][Full Text] [Related]
12. RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists.
Bley KR; Bhattacharya A; Daniels DV; Gever J; Jahangir A; O'Yang C; Smith S; Srinivasan D; Ford AP; Jett MF
Br J Pharmacol; 2006 Feb; 147(3):335-45. PubMed ID: 16331286
[TBL] [Abstract][Full Text] [Related]
13. Selective Prostacyclin Receptor Agonist Selexipag, in Contrast to Prostacyclin Analogs, Does Not Evoke Paradoxical Vasoconstriction of the Rat Femoral Artery.
Morrison K; Haag F; Ernst R; Iglarz M; Clozel M
J Pharmacol Exp Ther; 2018 Jun; 365(3):727-733. PubMed ID: 29588339
[TBL] [Abstract][Full Text] [Related]
14. Sexual dimorphism in prostacyclin-mimetic responses within rat mesenteric arteries: A novel role for K
Baldwin SN; Forrester EA; McEwan L; Greenwood IA
Br J Pharmacol; 2022 Apr; 179(7):1338-1352. PubMed ID: 34766649
[TBL] [Abstract][Full Text] [Related]
15. Prostanoid receptors involved in the relaxation of human pulmonary vessels.
Walch L; Labat C; Gascard JP; de Montpreville V; Brink C; Norel X
Br J Pharmacol; 1999 Feb; 126(4):859-66. PubMed ID: 10193765
[TBL] [Abstract][Full Text] [Related]
16. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
Honorato Pérez J
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
[TBL] [Abstract][Full Text] [Related]
17. The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors.
Clapp LH; Gurung R
Prostaglandins Other Lipid Mediat; 2015 Jul; 120():56-71. PubMed ID: 25917921
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and expression profile of the prostaglandin I(2) receptor in the rat craniovascular system.
Myren M; Olesen J; Gupta S
Vascul Pharmacol; 2011; 55(1-3):50-8. PubMed ID: 21749934
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension.
Shen L; Patel JA; Norel X; Moledina S; Whittle BJ; von Kessler K; Sista P; Clapp LH
Biochem Pharmacol; 2019 Aug; 166():242-252. PubMed ID: 31158340
[TBL] [Abstract][Full Text] [Related]
20. Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics.
Chow KB; Wong YH; Wise H
Br J Pharmacol; 2001 Dec; 134(7):1375-84. PubMed ID: 11724742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
